Kabra Drugs Ltd
₹0.00▲ +0.00 (+0.00%)
524322·NSE·Healthcare
Market Cap
56.21 Cr
PE Ratio
10.80
Volume
—
Day High - Low
—
52W High-Low
35.52 - 15.50
₹0.00▲ +0.00 (+0.00%)
Market Cap56.21 Cr
PE Ratio10.80
Volume—
Day High - Low—
52W High-Low35.52 - 15.50
Kabra Drugs Ltd (524322): company summary
Kabra Drugs Ltd (524322) is a micro-cap Healthcare company valued at ₹56 crore operating in Pharmaceuticals on the NSE and BSE.
Kabra Drugs Ltd (524322) is a micro-cap Healthcare company valued at ₹56 crore operating in Pharmaceuticals on the NSE and BSE.
- Financial performance
- Return on equity stands at 18.3%, a strong return on shareholder capital.
- Valuation multiples
- The stock trades at 10.8 times earnings, a discount to the Healthcare median of 32.5, 1.81 times book value.
Generated from DocStoX data. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
Not currently trading — we have seen no trades on NSE or BSE recently. It may be suspended, delisted, or renamed after a corporate action. Not a live price.
DocStoX Score
5.2/10
Weak
Fair Value
Sign in to see
ROE
18.30%
Strong
P/E
10.80x
Cheap
Debt / Equity
0.02
Low
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
52W₹15.50
₹35.52
DocStoX take
Supported by growth (10.0) and valuation (8.4), but held back by quality (1.2). Growth looks strong at 10.0, but that is offset by quality at 1.2. We are calling it Mixed rather than resolving the conflict for you. Scored on 4 of 5 measures.
DocStoX score
Medium confidence5.2
/10
Weak
Quality
Weak
ROE 18.3%
Valuation
Cheap
P/E 10.8×
Growth
Strong
Revenue +25.5% 10Y CAGR
Risk
Elevated
D/E 0.02
Momentum
No data
No technical indicators
Scored on 4 of 5 measures — the rest have no data for this company.
At a glance
Market Cap
₹56 Cr
52W High / Low
₹36 / ₹16
Dividend Yield
0.00%
Promoter Holding
0.00%
EPS (TTM)
₹-0.46
Book Value
₹12.49
Key highlights
- Profit compounding 67% a year
- Low leverage — D/E 0.02
- Revenue compounding 25% a year
- Loss-making in some of the last 5 years
- Quality is weak (1.2/10)
4 Positives3 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Kabra Drugs Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Kabra Drugs Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Related tools & concepts
Value Kabra Drugs Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing